Business Services

Leading clinical stage AI drug discovery company, Benevolent AI, has expanded its AI-driven drug discovery collaboration with AstraZeneca. This means that the number of disease areas being explored through the partnership will be doubled.

The expansion builds on the partnership initiated in 2019, and adds systemic lupus erythematosus (SLE) and heart failure (HF) to research on identifying multiple novel targets in chronic kidney disease (CKD) and idiopathic pulmonary fibrosis (IPF).

Abivax have received scientific advice from the EMA supporting advancing ABX464 into Phase III clinical testing, for the treatment of ulcerative colitis, and for subsequent potential marketing authorisation submission and commercialisation.

Basilea Pharmaceutica, announced that its license partner, Pfizer, has received a Drug Approval License from the National Medical Products Administration (NMPA) in China for its antifungal Cresemba (isavucanazole), for the treatment of adult patients with invasive aspergillosis.

The FDA has given Investigational New Drug (IND) clearance to atai Life Sciences, to conduct a clinical DDI study of PCN-101 (R-ketamine). The DDI trial will complement an existing Phase IIa trial in treatment-resistant depression (TRD) recently initiated in Europe.

AbbVie’s investigational telisotuzumab vedotin has been granted Breakthrough Therapy Designation by the FDA for the treatment of patients with advanced or metastatic epidermal growth factor receptor (EGFR) wild type, nonsquamous non-small cell lung cancer with high levels of c-Met overexpression whose disease has progressed on or after platinum-based therapy.

Cyclenium Pharma, an emerging pharmaceutical company, have announced a collaboration with Vuja De Sciences, to screen and optimise lead candidates to advance treatments uniquely suited for preventing cancer metastatic recurrence.